Polymedco, Inc, announced the availability of the BTA Stat test—a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor–associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. More »

Eating a concentrated extract of freeze-dried broccoli sprouts might inhibit bladder cancer by delivering a protective factor right where the bladder is most at risk. More »

Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant... More »

Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant... More »

TORONTO -- For high-risk bladder cancer, a decision on aggressive versus conservative therapy depends on age and quality-of-life preferences, according to investigators here. More »

BOSTON -- A history of gonorrhea may translate into a twofold increased risk of bladder cancer for men, researchers here reported. More »

ANN ARBOR, Mich. -- Bladder cancer is deadlier in blacks than whites, even when it is diagnosed early. More »

Drs. Henry, MacVicar, and Hussain provide a timely review of the current management of muscle-invasive and metastatic urothelial cancer. The emerging role of neoadjuvant chemotherapy and the promise of novel, less toxic targeted therapies are of particular interest in the treatment of a disease in which outcomes remain poor for locally advanced and metastatic involvement despite an aggressive multimodality approach.[1] We wish to briefly comment on three issues raised by the authors: (1) the... More »

Optimal therapy for locally advanced bladder cancer aims to prevent local recurrence, reduce the probability of distant metastasis, and improve survival. Radical cystectomy coupled with a pelvic lymph node dissection is the mainstay treatment of locally invasive bladder cancer, curing the majority of patients with organ-confined bladder tumors, about half with extravesical disease, and a significant minority with lymph node metastases. Although radical cystectomy provides good local and regional... More »

Bladder cancer is the fifth most common cancer diagnosed in the United States. Prognosis for this disease is dependent on both tumor stage and grade. Radical cystectomy has been the standard treatment for muscle-invasive local disease; however, combined-modality approaches with the use of chemotherapy are gaining momentum with data suggesting survival improvement. Patients with metastatic disease have poor long-term survival rates despite systemic multiagent chemotherapy. A variety of agents,... More »